News Shionogi's diversification continues with $2bn IntraBio buy Shionogi has reached a $2bn agreement to buy Anglo-US biotech IntraBio and its recently approved Aqneursa therapy for two rare genetic disorders.
News Novo faces delay in US review of haemophilia drug The FDA has extended its review of Novo's experimental haemophilia A drug denecimig because of ongoing remediation work at a manufacturing facility.
News CSL joins forces with Alentis on claudin candidate CSL has licensed rights to a potentially first-in-class anti-claudin-1 antibody developed by Alentis in a deal that could be worth up to $1.55bn.
News Bayer pledges $2.2bn to US manufacturing facility Bayer has joined the ranks of pharma groups planning major facility investments in the US, with a $2.2bn plan for a new production unit in Ohio.
News Novartis taps China's Abogen for autoimmunity TCE Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
News Everlywell rolls out Clairity AI for breast cancer in US Digital health firm Everlywell is rolling out a Clairity AI, which can assess the risk of developing breast cancer from a mammogram, across the US.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.